MAPT and Alzheimer disease: Phosphorylated tau at the site of Thr181 is recently recognized as a novel biomarker for AD diagnosis [74], while the hyperphosphorylation of tau protein at other sites, such as Thr205, Ser396 and Ser404, is also closely correlated with AD pathology [75].